(Ublituximab) - 药物靶点：CD20_在研适应症：复发性多发性硬化，难治性慢性淋巴细胞白血病，套细胞淋巴瘤_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Rituximab biobetter、Rituximab biobetter - TG Therapeutics、Ublituximab (USAN/INN)

+ [10]

靶点

CD20

作用机制

CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、ADCC(抗体依赖的细胞毒作用)、CD20定向的溶细胞作用

治疗领域

免疫系统疾病神经系统疾病其他疾病+ [2]

在研适应症

复发性多发性硬化难治性慢性淋巴细胞白血病套细胞淋巴瘤+ [1]

非在研适应症

滤泡性淋巴瘤边缘区B细胞淋巴瘤视神经脊髓炎+ [5]

原研机构

rEVO Biologics, Inc.LFB Biotechnologies SASU

在研机构

TG Therapeutics, Inc.

AstraZeneca PLC

Ildong Pharmaceutical Co., Ltd.

+ [1]

非在研机构

Laboratoire Français du Fractionnement et des Biotechnologies

The Johns Hopkins University

最高研发阶段批准上市

首次获批日期

美国 (2022-12-28),

复发性多发性硬化

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看首次获批时间轴

序列信息

Sequence Code 15059H

来源: *****

Sequence Code 4724843L

来源: *****

关联

35

项与 Ublituximab 相关的临床试验

NCT05877963 / Recruiting临床3期

Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab (ENHANCE)

The primary purpose of this phase 3b study is to assess efficacy after transition from a current DMT to ublituximab, as measured by T1 Gadolinium (Gd)-enhancing lesions.

开始日期2023-06-13

申办/合作机构

TG Therapeutics, Inc.

NCT04635683 / Withdrawn临床1期IIT

A Phase I Trial of Lenalidomide, Umbralisib and Ublituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

This phase I trial studies the safety and how effective the combination of ublituximab, umbralisib, and lenalidomide is in certain types of indolent (slow-growing) non-Hodgkin's lymphoma or mantle cell lymphoma. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide may also stop the growth of non-Hodgkin's lymphoma by blocking blood flow to the cancer. Umbralisib is designed to block a protein called PI3 kinase in order to stop cancer growth and cause changes in the immune system that may allow the immune system to better act against cancer cells. Ublituximab is an antibody that attaches to the lymphoma cells and triggers immune reactions that may result in the death of the targeted lymphoma cells.

开始日期2022-09-30

申办/合作机构-

NCT04692155 / Terminated临床1/2期IIT

Phase Ib/II Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)

This is a single arm, multi-center, open label Phase Ib/II trial in adult patients with newly diagnosed Mantle Cell Lymphoma (MCL)(Stage II-IV). The Diagnosis of MCL (Stage II, III, IV) is supported by histology and over expression of cyclin D1 or by FISH (fluorescent in situ hybridization). In the proposed study, the primary endpoint is to estimate the biological response rate of the combination of Umbralisib at dose 800 mg with Ublituximab (900mg)-Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP), but a phase Ib portion with dose de-escalation at two does level (800 and 600 mg) will be built in to further confirm its safety and tolerability. Treatment will be administered on an outpatient basis in 3-week (21 day) cycles. Once Umbralisib dose is defined in phase Ib, the study will expand to phase II portion after SMC/DSMB (Safety monitoring committee/Data Safety Monitoring Committee) agreement.

开始日期2021-08-31

申办/合作机构

The University of Alabama at Birmingham

100 项与 Ublituximab 相关的临床结果

登录后查看更多信息

100 项与 Ublituximab 相关的转化医学

登录后查看更多信息

100 项与 Ublituximab 相关的专利（医药）

登录后查看更多信息

69

项与 Ublituximab 相关的文献（医药）

2024-04-01·Journal of neurology

Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment

Review

作者: Linker, Ralf A ; Faissner, Simon ; Rammohan, Kottil ; Delgado, Silvia R

Abstract:

The recent success of anti-CD20 monoclonal antibody therapies in the treatment of multiple sclerosis (MS) has highlighted the role of B cells in the pathogenesis of MS. In people with MS, the inflammatory characteristics of B-cell activity are elevated, leading to increased pro-inflammatory cytokine release, diminished anti-inflammatory cytokine production and an accumulation of pathogenic B cells in the cerebrospinal fluid. Rituximab, ocrelizumab, ofatumumab, ublituximab and BCD-132 are anti-CD20 therapies that are either undergoing clinical development, or have been approved, for the treatment of MS. Despite CD20 being a common target for these therapies, differences have been reported in their mechanistic, pharmacological and clinical characteristics, which may have substantial clinical implications. This narrative review explores key characteristics of these therapies. By using clinical trial data and real-world evidence, we discuss their mechanisms of action, routes of administration, efficacy (in relation to B-cell kinetics), safety, tolerability and convenience of use. Clinicians, alongside patients and their families, should consider the aspects discussed in this review as part of shared decision-making discussions to improve outcomes and health-related quality of life for people living with MS.

2024-02-01·Multiple sclerosis and related disorders

Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis

Review

作者: Kang, Angray S ; Giovannoni, Gavin ; Baker, David ; Schmierer, Klaus

Neutropenia serves as a risk factor for severe infection and is a consequence of some immune-depleting immunotherapies. This occurs in people with multiple sclerosis following chemotherapy-conditioning in haematopoietic stem cell transplantation and potent B cell targeting agents. Whilst CD52 is expressed by neutrophils and may contribute to early-onset neutropenia following alemtuzumab treatment, deoxycytidine kinase and CD20 antigen required for activity of cladribine tablets, off-label rituximab, ocrelizumab, ofatumumab and ublituximab are not or only weakly expressed by neutrophils. Therefore, alternative explanations are needed for the rare occurrence of early and late-onset neutropenia following such treatments. This probably occurs due to alterations in the balance of granulopoiesis and neutrophil removal. Neutrophils are short-lived, and their removal may be influenced by drug-associated infections, the killing mechanisms of the therapies and amplified by immune dyscrasia due to influences on neutropoiesis following growth factor rerouting for B cell recovery and cytokine deficits following lymphocyte depletion. This highlights the small but evident neutropenia risks following sustained B cell depletion with some treatments.

2024-01-23·Blood advances

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

Article

作者: Mulford, Deborah A ; Zent, Clive S ; Liesveld, Jane L ; Barr, Paul M ; Gordan, Leo ; Winter, Allison ; Wallace, Danielle S ; Ma, Shuo ; Hill, Brian T ; Friedberg, Jonathan W ; Karmali, Reem ; Miskin, Hari P ; Winter, Jane ; Sportelli, Peter ; Baran, Andrea M ; Rowland, Chris ; Weiss, Michael S ; Bui, Andrew ; Advani, Anjali

Abstract:

Many patients with chronic lymphocytic leukemia (CLL) will develop treatment resistance to Bruton tyrosine kinase (BTK) inhibitors. Phosphatidylinositol-3-kinase (PI3K) inhibitors, including umbralisib, have significant clinical activity in relapsed/refractory CLL, but prolonged exposure is associated with potential toxicities. Owing to the synergistic antitumor effects of combined PI3K and BCL-2 inhibition, we sought to explore the feasibility of response-adapted, time-limited therapy to optimize disease control while mitigating the risks of prolonged treatment. We conducted a phase 1/2 clinical trial to determine the safety and efficacy of venetoclax in combination with umbralisib and the anti-CD20 monoclonal antibody, ublituximab, (U2-VeN) in patients with relapsed/refractory CLL (N = 46) and Richter transformation (N = 5). After 12 cycles, treatment was stopped for patients with CLL who achieved undetectable minimal residual disease (uMRD). Adverse events of special interest included diarrhea in 50% of patients (11% grade 3/4), and aspartate aminotransferase and/or alanine aminotransferase elevation in 15 patients (33%), with 3 (7%) grade 3/4. There were no cases of tumor lysis syndrome related to venetoclax, with outpatient initiation in 96% of patients. The intent-to-treat overall response rate for CLL was 98% with best response of 100% in evaluable patients (42% complete responses). The end-of-treatment rate of uMRD at 10−4 in bone marrow was 77% (30/39), including a 71% uMRD rate among 14 patients refractory to prior BTK inhibitor. Time-limited venetoclax and U2 is safe and highly effective combination therapy for patients with relapsed/refractory CLL including those who have been previously treated with covalent BTK inhibitors. This trial was registered on www.clinicaltrials.gov as #NCT03379051.

159

项与 Ublituximab 相关的新闻（医药）

2024-06-25

·Firstwordpharma

EU greenlights subcutaneous version of Roche’s Ocrevus to treat multiple sclerosis

The European Commission approved the subcutaneous (SC) formulation of Roche’s Ocrevus (ocrelizumab) to treat relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), maintaining the same twice-yearly dosing schedule as the intravenous (IV) version. The company noted Tuesday that the new formulation is intended to be administered by healthcare providers, either in the clinic or in other settings.“Now, people in the EU with multiple sclerosis can have their medicine administered in just 10 minutes twice per year without needing an IV facility,” making “it easier for more people…to access their treatment, while also saving time for providers,” said Levi Garraway, chief medical officer at Roche.The approval was backed by findings from the Phase III OCARINA II study, which showed that SC Ocrevus resulted in non-inferior blood levels, alongside a comparable safety and efficacy profile to the IV formulation. Moreover, over 92% of study participants surveyed reported being satisfied or very satisfied with the SC formulation.The SC version of the anti-CD20 antibody, which uses Halozyme's Enhanze drug delivery technology, is also awaiting a decision by the FDA in September. In a Firstword poll of US neurologists conducted last year, nearly a third of respondents said they would use SC Ocrevus exclusively over the IV version if approved, and half of those surveyed believed the Ocrevus franchise would gain a significant advantage over other anti-CD20 competitors such as Novartis’ Kesimpta (ofatumumab) and TG Therapeutics’ Briumvi (ublituximab).Ocrevus remains Roche’s top-selling drug, racking up CHF 6.4 billion ($7.1 billion) in global sales last year, with the EU accounting for nearly CHF 1.1 billion ($1.2 billion) of it.

临床3期临床结果上市批准

2024-06-07

·GlobeNewswire-Health Care

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Fireside chat scheduled for Tuesday, June 11, 2024, at 1:20 PM ETNEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, being held at the Loews Miami Beach Hotel, Miami Beach, FL on June 10-13, 2024. The fireside chat is scheduled to take place on Tuesday, June 11, 2024, at 1:20 PM ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events. ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn. BRIUMVI® is a registered trademark of TG Therapeutics, Inc. CONTACT: Investor RelationsEmail: ir@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 4 Media Relations:Email: media@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 6

上市批准

2024-06-07

·BioSpace

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceFireside chat scheduled for Tuesday, June 11, 2024, at 1:20 PM ET

NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, being held at the Loews Miami Beach Hotel, Miami Beach, FL on June 10-13, 2024. The fireside chat is scheduled to take place on Tuesday, June 11, 2024, at 1:20 PM ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at . ABOUT TG THERAPEUTICS TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn. BRIUMVI® is a registered trademark of TG Therapeutics, Inc. CONTACT: Investor Relations Email: ir@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 4 Media Relations: Email: media@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 6

上市批准

100 项与 Ublituximab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11243	Ublituximab	-	DB11850

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
复发性多发性硬化	美国	TG Therapeutics, Inc.	2022-12-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
弥漫性大B细胞淋巴瘤	临床3期	美国	TG Therapeutics, Inc.	2016-05-25
弥漫性大B细胞淋巴瘤	临床3期	澳大利亚	TG Therapeutics, Inc.	2016-05-25
弥漫性大B细胞淋巴瘤	临床3期	以色列	TG Therapeutics, Inc.	2016-05-25
弥漫性大B细胞淋巴瘤	临床3期	意大利	TG Therapeutics, Inc.	2016-05-25
弥漫性大B细胞淋巴瘤	临床3期	波兰	TG Therapeutics, Inc.	2016-05-25
弥漫性大B细胞淋巴瘤	临床3期	斯洛伐克	TG Therapeutics, Inc.	2016-05-25
弥漫性大B细胞淋巴瘤	临床3期	韩国	TG Therapeutics, Inc.	2016-05-25
弥漫性大B细胞淋巴瘤	临床3期	西班牙	TG Therapeutics, Inc.	2016-05-25
弥漫性大B细胞淋巴瘤	临床3期	英国	TG Therapeutics, Inc.	2016-05-25
滤泡性淋巴瘤	临床3期	美国	TG Therapeutics, Inc.	2016-05-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02612311 (CTgov)	临床3期	慢性淋巴细胞白血病	603	Ublituximab+Umbralisib (Experimental: Arm A: Ublituximab + Umbralisib)	鬱淵鬱鏇網鹹選壓醖蓋(繭糧鹹膚鏇簾願鏇糧鬱) = 餘積獵壓鹽憲製蓋醖糧艱鏇鬱糧窪膚糧憲壓繭 (鏇顧壓鹹淵範壓窪蓋鹹, 衊淵憲鑰夢衊構淵鹹選 ~ 鹹淵餘願餘齋鹽顧繭選) 更多	-	2024-05-07
				Obinutuzumab+Chlorambucil (Active Comparator: Arm B: Obinutuzumab + Chlorambucil)	鬱淵鬱鏇網鹹選壓醖蓋(繭糧鹹膚鏇簾願鏇糧鬱) = 壓遞鬱觸醖顧網顧觸願艱鏇鬱糧窪膚糧憲壓繭 (鏇顧壓鹹淵範壓窪蓋鹹, 艱醖齋獵夢憲構鹹衊鑰 ~ 蓋鑰窪願願顧夢壓衊蓋) 更多
NCT03801525 (ULTRA-V, CTgov)	临床2/3期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤	277	Ublituximab+Venetoclax+Umbralisib (Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V))	糧鹽製鏇醖淵願鏇積憲(積膚願襯餘顧製憲製鏇) = 廠窪壓鹹糧鬱鬱製築構艱鹽鹽鬱膚願遞選鬱淵 (鏇糧築衊構蓋夢簾獵製, 範築遞鏇窪廠鏇蓋襯齋 ~ 鑰衊構觸鹹憲網鹹蓋網) 更多	-	2024-04-19
				Ublituximab+Venetoclax+Umbralisib (Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V))	衊觸夢醖膚艱鹹鑰網廠(襯鹹艱廠選選觸襯醖願) = 鹹鏇鏇壓鏇壓糧選淵範積觸鹹夢夢憲範艱壓鏇 (襯餘鏇淵簾憲築積壓簾, 顧鹽憲艱網簾襯鑰醖積 ~ 製獵繭鑰簾構蓋積廠顧) 更多
NCT05877963 (ENHANCE, ACTRIMS2024) 人工标引	临床3期	复发性多发性硬化	-	Ublituximab 450 mg infusion, 2 hr	廠獵網壓鏇構鏇窪淵淵(構餘鹽窪獵壓壓餘積鏇) = 繭醖獵夢製廠艱簾鑰醖餘艱鹽餘餘襯網襯壓衊 (繭夢艱簾艱艱範衊餘願 )	积极	2024-02-29
				Ublituximab 450 mg infusion, 1 hr	廠獵網壓鏇構鏇窪淵淵(構餘鹽窪獵壓壓餘積鏇) = 築夢觸廠膚觸淵網餘願餘艱鹽餘餘襯網襯壓衊 (繭夢艱簾艱艱範衊餘願 )
NCT04508647 (CTgov)	临床2期	滤泡性淋巴瘤 \| 边缘区B细胞淋巴瘤	4	Ublituximab (Ublituximab Only)	廠範衊蓋餘鑰壓餘簾構(鑰壓壓構餘鑰壓齋繭築) = 餘廠廠醖衊鑰窪壓範鬱選壓淵網遞製壓窪襯顧 (壓構憲憲廠積醖願觸齋, 鏇鏇簾遞選憲築襯構製 ~ 製鹽膚鑰鏇窪餘觸鑰鹹) 更多	-	2023-11-09
				Ublituximab+Umbralisib (Ublituximab First, Then Ublituximab and Umbralisib)	廠範衊蓋餘鑰壓餘簾構(網獵衊遞襯築鑰築糧範) = 構艱艱鬱窪鬱鏇壓鑰遞壓構獵餘醖醖艱築襯簾 (餘鬱製淵廠願範積憲築, 蓋淵齋構齋襯窪衊壓齋 ~ 壓廠築鬱鏇繭鹹願鏇蓋) 更多
ULTIMATE I & II (ECTRIMS2023)	临床3期	CD20	-	Ublituximab 450 mg	夢獵製廠襯獵積壓壓選(夢淵膚鏇遞餘淵構廠積) = 憲築衊鑰製憲餘鹹鹽鹽簾夢獵齋膚醖簾觸選網 (醖膚夢膚鏇選廠鑰鹽顧, -0.82 ~ 13.46) 更多	积极	2023-09-30
				Teriflunomide 14 mg	夢獵製廠襯獵積壓壓選(夢淵膚鏇遞餘淵構廠積) = 窪獵範餘淵膚願鏇鏇憲簾夢獵齋膚醖簾觸選網 (醖膚夢膚鏇選廠鑰鹽顧, 17.77 ~ 31.96) 更多
NCT04692155 (CTgov)	临床1/2期	套细胞淋巴瘤	1	Ublituximab+Umbralisib	衊遞鑰醖製築夢鏇鹹廠(膚襯觸觸襯壓構廠製鑰) = 鹽築繭醖鏇鑰積鹽淵鹽襯蓋艱顧獵築窪獵淵齋 (夢淵鑰醖餘鹹繭糧遞製, 繭糧網憲築膚獵鏇廠艱 ~ 繭糧獵鏇膚製簾願夢願) 更多	-	2023-09-28
NCT04016805 (CTgov)	临床2期	慢性淋巴细胞白血病	41	Ibrutinib+Ublituximab+Umbralisib (Ublituximab + Umbralisib + Ibrutinib)	襯艱餘襯獵蓋膚艱積鹽(糧簾簾壓襯繭夢積廠憲) = 鏇觸蓋廠艱襯顧淵製積鏇繭製願鏇築簾鏇醖蓋 (顧壓衊膚鏇蓋壓製醖範, 鑰壓遞壓鬱遞膚膚積願 ~ 簾網簾觸網糧鬱願簾鏇) 更多	-	2023-07-24
				Ublituximab+Venetoclax+Umbralisib (Ublituximab + Umbralisib + Venetoclax)	襯艱餘襯獵蓋膚艱積鹽(糧簾簾壓襯繭夢積廠憲) = 糧醖膚蓋糧範鬱鹹鏇選鏇繭製願鏇築簾鏇醖蓋 (顧壓衊膚鏇蓋壓製醖範, 願鹹艱淵衊廠淵壓膚餘 ~ 蓋襯壓鏇願選壓觸襯鑰) 更多
NCT03828448 (CTgov)	临床2期	小淋巴细胞淋巴瘤 \| 滤泡性淋巴瘤	34	Ublituximab+Umbralisib	齋夢獵鹹繭壓窪繭糧憲(網蓋繭鑰鑰鹽鏇鏇構鬱) = 獵願構網衊醖糧鏇遞繭醖鏇鹹製遞顧顧範鹽鹹 (淵積窪簾憲窪鏇鑰壓選, 壓簾鑰製鬱鹹淵醖窪廠 ~ 憲鹹築蓋窪繭醖蓋遞襯) 更多	-	2023-07-24
EMA 人工标引	N/A	复发-缓解型多发性硬化	1,089	Ublituximab (ULTIMATE I)	鏇繭鹽構顧簾餘鬱顧鬱(鹹繭鬱繭願鑰製衊選繭) = 網糧範鏇築糧襯積鏇襯壓糧鏇蓋憲顧範遞築窪 (鹽糧淵鹽窪製壓遞願簾 ) 更多	积极	2023-07-13
				Teriflunomide (ULTIMATE I)	鏇繭鹽構顧簾餘鬱顧鬱(鹹繭鬱繭願鑰製衊選繭) = 憲壓觸衊獵蓋範淵醖構壓糧鏇蓋憲顧範遞築窪 (鹽糧淵鹽窪製壓遞願簾 ) 更多
NCT02656303 (CTgov)	临床2期	慢性淋巴细胞白血病	116	Ublituximab+Umbralisib (Parent Study Arm B)	觸鏇夢簾簾餘蓋憲鏇壓(齋願糧糧範鏇艱襯觸窪) = 顧蓋鬱觸遞鹹窪鬱構醖鬱鑰繭鏇廠獵夢艱窪鑰 (壓築鬱鏇繭製蓋糧繭膚, 鑰繭艱簾網憲積簾窪構 ~ 顧獵遞構鏇鬱憲鏇範鹽) 更多	-	2023-06-22
				Ublituximab+Umbralisib (Parent Study Arm C)	觸鏇夢簾簾餘蓋憲鏇壓(齋願糧糧範鏇艱襯觸窪) = 簾憲鏇範壓築遞鬱簾構鬱鑰繭鏇廠獵夢艱窪鑰 (壓築鬱鏇繭製蓋糧繭膚, 選醖築繭艱衊廠廠鹽網 ~ 廠糧蓋壓願壓願網範願) 更多